Gliflozina (Catalan Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gliflozina" in Catalan language version.

refsWebsite

Global rank Catalan rank

2^nd place

6^th place

4^th place

7^th place

low place

932^nd place

aemps.gob.es

«Centro de Información online de Medicamentos de la AEMPS - CIMA». Madrid: AEMPS. Ministerio de Sanidad, Servicios Sociales e Igualdad, 2024.

Shubrook, Jay; Baradar-Bokaie, Babak; Adkins, Sarah «Empagliflozin in the treatment of type 2 diabetes: Evidence to date». Drug Design, Development and Therapy, 9, 2015, pàg. 5793–803. DOI: 10.2147/DDDT.S69926. PMC: 4634822. PMID: 26586935.
Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen «Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis». European Journal of Preventive Cardiology, 25, 5, 2018, pàg. 495–502. DOI: 10.1177/2047487318755531. PMID: 29372664.
«Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence». Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 2020, pàg. 161–174. DOI: 10.2147/DMSO.S233538. PMC: 6982447. PMID: 32021362.
Scheen, André J. «Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus». Drugs, 75, 1, 2014, pàg. 33–59. DOI: 10.1007/s40265-014-0337-y. PMID: 25488697.

Shubrook, Jay; Baradar-Bokaie, Babak; Adkins, Sarah «Empagliflozin in the treatment of type 2 diabetes: Evidence to date». Drug Design, Development and Therapy, 9, 2015, pàg. 5793–803. DOI: 10.2147/DDDT.S69926. PMC: 4634822. PMID: 26586935.
Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen «Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis». European Journal of Preventive Cardiology, 25, 5, 2018, pàg. 495–502. DOI: 10.1177/2047487318755531. PMID: 29372664.
«Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence». Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 2020, pàg. 161–174. DOI: 10.2147/DMSO.S233538. PMC: 6982447. PMID: 32021362.
Scheen, André J. «Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus». Drugs, 75, 1, 2014, pàg. 33–59. DOI: 10.1007/s40265-014-0337-y. PMID: 25488697.